全文获取类型
收费全文 | 5007篇 |
免费 | 405篇 |
国内免费 | 60篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 146篇 |
妇产科学 | 210篇 |
基础医学 | 639篇 |
口腔科学 | 74篇 |
临床医学 | 433篇 |
内科学 | 1302篇 |
皮肤病学 | 113篇 |
神经病学 | 612篇 |
特种医学 | 167篇 |
外科学 | 455篇 |
综合类 | 6篇 |
一般理论 | 3篇 |
预防医学 | 295篇 |
眼科学 | 54篇 |
药学 | 341篇 |
中国医学 | 9篇 |
肿瘤学 | 573篇 |
出版年
2024年 | 19篇 |
2023年 | 142篇 |
2022年 | 285篇 |
2021年 | 432篇 |
2020年 | 252篇 |
2019年 | 273篇 |
2018年 | 321篇 |
2017年 | 205篇 |
2016年 | 233篇 |
2015年 | 258篇 |
2014年 | 267篇 |
2013年 | 312篇 |
2012年 | 415篇 |
2011年 | 348篇 |
2010年 | 189篇 |
2009年 | 140篇 |
2008年 | 233篇 |
2007年 | 240篇 |
2006年 | 200篇 |
2005年 | 167篇 |
2004年 | 143篇 |
2003年 | 131篇 |
2002年 | 99篇 |
2001年 | 19篇 |
2000年 | 6篇 |
1999年 | 22篇 |
1998年 | 24篇 |
1997年 | 14篇 |
1996年 | 11篇 |
1995年 | 11篇 |
1994年 | 12篇 |
1993年 | 9篇 |
1992年 | 2篇 |
1991年 | 5篇 |
1990年 | 5篇 |
1989年 | 3篇 |
1988年 | 6篇 |
1987年 | 4篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1979年 | 3篇 |
排序方式: 共有5472条查询结果,搜索用时 27 毫秒
51.
52.
53.
Manuel Menzocchi Giulia Paoletti Alexa Huber Giancarlo Carli Francesca I. Cavallaro Diego Manzoni 《The International journal of clinical and experimental hypnosis》2013,61(1):122-135
In highly hypnotizable individuals (highs), postural control is more independent of sensory information than in low hypnotizable subjects (lows). The aim of the study was to find out whether locomotion is also less affected in highs than in lows by visual suppression and changes in the neck proprioceptive input. Eighteen highs and 20 lows were asked to walk straight ahead, blindfolded, in basal conditions (face forward), during real and imagined right/left head rotation and mental computation. Highs detected deviations from the straight trajectory better than lows. Their walking direction was more straight during basal conditions and less influenced than the lows' one by mental computation and real/imagined rotation of the head. The results confirm highs' lower dependence on sensory inputs, although this cannot be definitely attributed to a better internal representation of space or to higher behavioral automaticity. 相似文献
54.
Giuseppe Fanetti Giulia Marvaso Delia Ciardo Annaisabel Rese Rosalinda Ricotti Elena Rondi Stefania Comi Federica Cattani Dario Zerini Cristiana Fodor Ottavio de Cobelli Roberto Orecchia Barbara A. Jereczek-Fossa 《Medical oncology (Northwood, London, England)》2018,35(5):75
To evaluate outcome in patients treated with stereotactic body radiotherapy (SBRT) on bone oligometastases from castration-sensitive prostate cancer after primary treatment. We retrospectively collected data of patients with less than five lesions at time of SBRT and hormone-naïve disease at the first extra-regional localization, treated between 03/2012 and 11/2016. Prostate-specific antigen (PSA) was measured every 3 months after SBRT. Imaging was performed in case of progression. Survival analysis was performed with Kaplan–Meier (log-rank test) approach. Fifty-five patients were treated on 77 bone oligometastases. Median age, initial PSA and pre-SBRT PSA were 72 years, 9.12 and 3.5 ng/mL, respectively. Twenty-five patients (45%) received SBRT alone while the remaining 30 patients (55%) received concomitant ADT. Median follow-up was 24.6 months (range 3.0–67.2 months). No acute or late toxicity of grade?>?1 was reported. Clinical progression was observed in 38 (69%) patients. 1-year biochemical progression-free survival (b-PFS), clinical progression-free survival (c-PFS), prostate-specific survival (PCSS) and local control (LC) rates were 51, 56, 100 and 83%, respectively. Comparing patients treated with SBRT alone and with concomitant ADT, no significant differences were found for those outcomes. SBRT is safe and allows high 1-year LC rate (83%) with low toxicity profile. No significant improvement in outcomes was registered with the addition of ADT to SBRT. 相似文献
55.
56.
57.
58.
Emanuele Angelucci Valeria Santini Anna Angela Di Tucci Giulia Quaresmini Carlo Finelli Antonio Volpe Giovanni Quarta Flavia Rivellini Grazia Sanpaolo Daniela Cilloni Flavia Salvi Giovanni Caocci Alfredo Molteni Daniele Vallisa Maria Teresa Voso Susanna Fenu Lorenza Borin Giancarlo Latte Giuliana Alimena Sergio Storti Alfonso Piciocchi Paola Fazi Marco Vignetti Sante Tura 《European journal of haematology》2014,92(6):527-536
59.
Inflammatory bowel disease in chronic granulomatous disease: An emerging problem over a twenty years' experience
下载免费PDF全文
![点击此处可从《Pediatric allergy and immunology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Giulia Angelino Paola De Angelis Simona Faraci Francesca Rea Erminia Francesca Romeo Filippo Torroni Renato Tambucci Alessia Claps Paola Francalanci Maria Chiriaco Gigliola Di Matteo Caterina Cancrini Paolo Palma Patrizia D'Argenio Luigi Dall'Oglio Paolo Rossi Andrea Finocchi 《Pediatric allergy and immunology》2017,28(8):801-809
60.
Licia Iaccarino Tiziana Ottone Valentina Alfonso Laura Cicconi Mariadomenica Divona Serena Lavorgna Serena Travaglini Aleandra Ferrantini Giulia Falconi Constance Baer Monica Usai Fabio Forghieri Adriano Venditti Maria Ilaria Del Principe William Arcese Maria Teresa Voso Torsten Haferlach Francesco Lo-Coco 《American journal of hematology》2019,94(10):1091-1097
Despite the high probability of cure of patients with acute promyelocytic leukemia (APL), mechanisms of relapse are still largely unclear. Mutational profiling at diagnosis and/or relapse may help to identify APL patients needing frequent molecular monitoring and early treatment intervention. Using an NGS approach including a 31 myeloid gene-panel, we tested BM samples of 44 APLs at the time of diagnosis, and of 31 at relapse. Mutations in PML and RARA genes were studied using a customized-NGS-RNA panel. Patients relapsing after ATRA-chemotherapy rarely had additional mutations (P = .009). In patients relapsing after ATRA/ATO, the PML gene was a preferential mutation target. We then evaluated the predictive value of mutations at APL diagnosis. A median of two mutations was detectable in 9/11 patients who later relapsed, vs one mutation in 21/33 patients who remained in CCR (P = .0032). This corresponded to a significantly lower risk of relapse in patients with one or less mutations (HR 0.046; 95% CI 0.011-0.197; P < .0001). NGS-analysis at the time of APL diagnosis may inform treatment decisions, including alternative treatments for cases with an unfavorable mutation profile. 相似文献